Celgene's Multiple Myeloma Triplet Succeeds in Key Phase III Trial Post author:Sam Post published:February 5, 2018 Post category:BioPharma The international clinical study, OPTIMISMM, achieved its primary endpoint. Source: BioSpace You Might Also Like New Jersey Implant Maker Braeburn Pharma Yanks Plans for $150 Million IPO February 2, 2017 Agile Therapeutics, Inc. Reports Fourth Quarter And Full Year 2016 Financial Results March 8, 2017 Bay Area's IMPAX Labs Surges on Merger Buzz September 21, 2017
